GlassScriptPhysician profile
Amber J Wade
NPI 1568862001
$12,123.36
in general payments reported to CMS, 2019-2025
59 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,221 · 2022: $2,134 · 2023: $2,623 · 2024: $2,069 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,412 · Education: $189 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,412.16 |
| Education | $188.99 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,695.55 | 2021-2024 | Kisqali |
| Merck Sharp & Dohme LLC | $756.30 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $685.23 | 2021-2025 | |
| Janssen Biotech, INC. | $605.41 | 2021-2025 | Erleada, Balversa, Darzalex |
| Amgen INC. | $572.20 | 2021-2023 | Kyprolis, Blincyto, Xgeva |
| Eisai INC. | $560.49 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $542.00 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Seagen INC. | $525.84 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Incyte Corporation | $476.47 | 2021-2025 | Pemazyre, Monjuvi, Jakafi |
| Gilead Sciences, INC. | $444.75 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $426.93 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $371.08 | 2021-2025 | Ninlaro, Iclusig |
| Glaxosmithkline, LLC. | $324.21 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $295.88 | 2022-2025 | Opdualag, Opdivo, Augtyro |
| Beigene USA, INC. | $294.83 | 2021-2025 | Brukinsa, Tevimbra |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $289.41 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $283.70 | 2021-2025 | Venclexta, Polivy, Tecentriq |
| Abbvie INC. | $251.35 | 2021-2025 | |
| Lilly USA, LLC | $221.29 | 2021-2025 | Jaypirca, Verzenio |
| Genzyme Corporation | $195.36 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $182.11 | 2023-2025 | Clonoseq |
| Abbott Laboratories | $166.01 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.10 | 2023-2025 | |
| Genmab U.S., INC. | $99.54 | 2023-2025 | Epkinly |
| Janssen Pharmaceuticals, INC | $94.73 | 2021-2023 | Xarelto |
| Pharmacyclics LLC, An Abbvie Company | $92.14 | 2021-2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.00 | 2021-2025 | |
| Legend Biotech USA INC. | $88.57 | 2024-2025 | Carvykti |
| Array Biopharma INC | $86.61 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Astellas Pharma US INC | $86.37 | 2022-2025 | Xtandi, Padcev |
| Taiho Oncology, INC. | $85.03 | 2023-2025 | |
| Stemline Therapeutics INC. | $80.36 | 2023-2024 | Orserdu |
| Jazz Pharmaceuticals INC. | $78.29 | 2021-2022 | |
| Foundation Medicine, INC. | $77.17 | 2022-2023 | Foundationone Cdx |
| Emd Serono, INC. | $76.15 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $68.28 | 2021-2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $63.14 | 2022-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $60.81 | 2023-2024 | Orgovyx |
| Exelixis INC. | $56.82 | 2021-2022 | |
| Kyowa Kirin, INC. | $56.04 | 2021-2023 | Poteligeo |
| Servier Pharmaceuticals LLC | $53.09 | 2022-2024 | |
| Catalyst Pharmaceuticals, INC. | $48.68 | 2023 | Firdapse |
| Caris Mpi, INC. | $40.10 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $36.00 | 2022-2023 | Myrisk |
| Coherus Oncology, INC. | $32.99 | 2021 | |
| Mirati Therapeutics, INC. | $31.84 | 2023 | Krazati |
| Iovance Biotherapeutics, INC. | $30.89 | 2025 | Amtagvi |
| Kite Pharma, INC. | $29.93 | 2025 | Yescarta |
| Boston Scientific Corporation | $28.82 | 2024 | Spaceoar Vue System - 10ml |
| Tempus Ai, INC | $28.76 | 2024 | Xt Cdx |
| Beone Medicines USA, INC. | $23.42 | 2025 | Tevimbra |
| Adc Therapeutics America, INC. | $22.53 | 2024 | |
| Syndax Pharmaceuticals, INC. | $19.77 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $17.17 | 2022 | |
| Puma Biotechnology, INC. | $16.27 | 2025 | |
| Sun Pharmaceutical Industries INC. | $15.69 | 2023 | Yonsa, Odomzo |
| Sanofi-Aventis U.S. LLC | $14.30 | 2021 | |
| Sobi, INC | $12.50 | 2022 | |
| Secura Bio, INC. | $8.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.